title: Persistence of solifenacin therapy in patients with overactive bladder in the clinical setting: a prospective, multicenter, observational study.
abstract: OBJECTIVE
  The aim of this study was to evaluate the persistence with solifenacin therapy over a 12-month period in patients with overactive bladder (OAB).
  
  
  METHODS
  This is a 52-week long, multicenter, prospective, observational study. The subjects were individuals ≥ 18 years old with OAB symptoms for ≥ 3 months, characterised by a total OAB Symptom Score (OABSS) of ≥ 3 and OABSS urgency item score of ≥ 2. Patients were prescribed 5 mg or 10 mg of solifenacin once daily for OAB symptoms. Drug persistence, reasons for discontinuation and factors related to the persistence were evaluated.
  
  
  RESULTS
  A total of 1018 patients (329 men, 689 women) with a mean age of 59 years were included. The 52-week drug persistence rate was 22.1%. The drug persistence rates at 12, 24 and 36 weeks were 72.4%, 45.8% and 31.1% respectively. The three most common reasons for discontinuing therapy included symptom improvement in 30.4%, lack of efficacy in 13.4%, and a switch to another antimuscarinic agent in 10.8%. Older patients (odds ratio = 1.02, 95% CI: 1.01-1.04), and female patients (odds ratio = 1.94, 95% CI: 1.37-2.75) were more likely to continue the medication over the 12-month period than were younger, male patients. The number of nocturia episodes was negatively correlated with drug persistence (odds ratio = 0.83, 95% CI: 0.71-0.97).
  
  
  CONCLUSIONS
  There was low persistence (22%) to solifenacin therapy for OAB symptoms over a 12-month period. Older patients, female patients and those with fewer episodes of nocturia were more persistent to therapy than were others.
authors.affiliation: Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
authors.forename: T H
authors.initials: TH
authors.lastname: Kim
authors.affiliation: Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
authors.forename: H W
authors.initials: HW
authors.lastname: You
authors.affiliation: Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
authors.forename: J H
authors.initials: JH
authors.lastname: Park
authors.affiliation: Department of Urology, Korea University College of Medicine, Seoul, Korea.
authors.forename: J G
authors.initials: JG
authors.lastname: Lee
authors.affiliation: Department of Urology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.
authors.forename: M-S
authors.initials: MS
authors.lastname: Choo
authors.affiliation: Department of Urology, Inha University College of Medicine, Incheon, Korea.
authors.forename: W H
authors.initials: WH
authors.lastname: Park
authors.affiliation: Department of Urology, Pusan National University Hospital, Pusan, Korea.
authors.forename: J Z
authors.initials: JZ
authors.lastname: Lee
authors.affiliation: Department of Urology, Keimyung University School of Medicine, Daegu, Korea.
authors.forename: C H
authors.initials: CH
authors.lastname: Park
authors.affiliation: Department of Urology, Chungnam National University School of Medicine, Daejeon, Korea.
authors.forename: Y G
authors.initials: YG
authors.lastname: Na
authors.affiliation: Department of Urology, Chonnam National University Medical School, Gwangju, Korea.
authors.forename: D D
authors.initials: DD
authors.lastname: Kwon
authors.affiliation: Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.|Department of Medical Device Management & Research, SAIHST, Sungkyunkwan University, Seoul, Korea.
authors.forename: K-S
authors.initials: KS
authors.lastname: Lee
mesh_terms: D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D000069464:Solifenacin Succinate / Q000627:therapeutic use*; D016896:Treatment Outcome; D053201:Urinary Bladder, Overactive / Q000188:drug therapy* / Q000503:physiopathology; D014563:Urodynamics / Q000187:drug effects*; D064804:Urological Agents / Q000627:therapeutic use
chemical_list: D064804:Urological Agents; D000069464:Solifenacin Succinate